Fujifilm Invests $1.6 Billion for Cell Culture Expansion

Fujifilm is preparing to invest $1.6 billion to ramp up the cell culture manufacturing services of its CDMO subsidiary Fujifilm Diosynth Biotechnologies.

Japan’s Fujifilm will invest about $850 million to accelerate the growth of...
Japan’s Fujifilm will invest about $850 million to accelerate the growth of its core bio CDMO subsidiary Fujifilm Diosynth Biotechnologies by expanding plants in the US and UK. Initial engineering studies are underway and the projects are due to begin operating by late 2023. (c) Fujifilm Diosynth Biotechnologies

Most of the funds will be funneled into the Japanese company’s Hillerød, Denmark, site but College Station, Texas, will also benefit. The upgrade will add 450 new jobs at Hillerød, bringing the total number of employees to 1,055.

Plans for investment in production equipment center on increasing capability for GMP batch manufacturing with the addition of eight 20,000-liter bioreactors and two downstream processing streams.

When the project is completed, the Hillerød business expects to be Europe’s largest end-to-end CDMO with 20 bioreactors of 20,000-l capacity for drug substance production.   

Fujifilm said the upgrade of the Danish site will also focus on sustainability, for example replacing an electric boiler with one powered by natural gas. The Diosynth Biotechnologies arm also will invest in technologies to cut water consumption.

Teiichi Goto, president and CEO of Fujifilm, said the further expansion of the bio CDMO business fits with the company’s strategy of leveraging both capital investment and technological innovation to meet the rapidly growing demand for high volume production of biopharmaceuticals.

By its own account, Fujifilm has invested more than $7.1 billion to expand its CDMO business over the past few years – the sum includes the acquisition of the Hillerød site from Biogen for $890 milion in August 2019. The healthcare business unit is now its largest in terms of sales revenue and operating profit.

Author: Dede Williams, Freelance Journalist

Company

Logo:

Fujifilm


Tokyo
Japan

Company contact







Whitepaper

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)
Setting the Standard

Excellence in Pharmaceutical Distribution and The Critical Role of Good Distribution Practice (GDP)

Are you ready to elevate your pharmaceutical operations? Download our exclusive whitepaper and discover how compliance with Good Distribution Practice (GDP) is essential for the safety and integrity of pharmaceuticals.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

most read

Photo
22.04.2025 • News

BASF Divests Two Joint Ventures in China

BASF has divested its shares in the joint venture companies, BASF Markor Chemical Manufacturing (Xinjiang) Co., Ltd. and Markor Meiou Chemical (Xinjiang) Co., Ltd. in Korla, China, to Verde Chemical Singapore Pte. Ltd.

Photo
19.03.2025 • News

Arkema Launches Acrylic Acid Purification Project

Arkema has announced the launch of its Carat Project at its Carling site in France. This initiative aims to enhance the capabilities and sustainability of the facility, which specializes in producing acrylic monomers and superabsorbent polymers.

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.